Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04356352 · ClinicalTrials.gov registry record · Phase 2
Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain
A Phase 2 study, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT04356352 is a Phase 2 study that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 33 participants.
The verdict
NCT04356352, a Phase 2 study, was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
The primary hypothesis is that esmolol and lidocaine, when given without the use of a tourniquet, provide relief of propofol injection pain that is superior to placebo when assessed using the propofol pain scoring tool
Interventions
- OTHER Placebo
- DRUG Lidocaine
- DRUG Esmolol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2020-09-09 |
| Est. Completion | 2023-08-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04356352
The ClinicalTrials.gov registry entry for NCT04356352 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04356352 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04356352 about?
NCT04356352 is a clinical study titled "Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain". The primary hypothesis is that esmolol and lidocaine, when given without the use of a tourniquet, provide relief of propofol injection pain that is superior to placebo when assessed using the propofol pain scoring tool
What is the current status of trial NCT04356352?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2020-09-09. Estimated completion is 2023-08-25.
What interventions are being tested in trial NCT04356352?
The interventions under investigation include: Placebo (OTHER), Lidocaine (DRUG), Esmolol (DRUG).
Who is sponsoring clinical trial NCT04356352?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.